Lenvatinib prolongs the progression‑free survival time of patients with intermediate‑stage hepatocellular carcinoma refractory to transarterial chemoembolization: A multicenter cohort study using data mining analysis
Shigeo Shimose(Kurume University), Takuji Torimura(Omuta hospital), Hironori Koga(Kurume University), Kazunori Noguchi(Omuta hospital), Kentaro Miyazaki(Osaka International University), Etsuko Moriyama(Kurume University), Hideya Suga(Yanagawa Rehabilitation Hospital), Masatoshi Tanaka(Fukushima Medical University), Hideki Iwamoto, Takashi Niizeki(Kurume University), Takumi Kawaguchi(Kurume University), Hiroyuki Suzuki(Kurume University), Taizo Yamaguchi, Tomotake Shirono(Kurume University), Yoshinori Yokokura(ShinKokura Hospital), Masahito Nakano(Kurume University)
Cited by 64
Related Papers
Therapeutic effects of restricted diet and exercise in obese patients with fatty liver
|Journal of Hepatology|1997|614
Clinical practice guidelines for hepatocellular carcinoma: The Japan Society of Hepatology 2017 (4th JSH‐HCC guidelines) 2019 update
|Hepatology Research|2019|539
Hepatitis C Virus Down-Regulates Insulin Receptor Substrates 1 and 2 through Up-Regulation of Suppressor of Cytokine Signaling 3
|American Journal Of Pathology|2004|536
Aerobic vs. resistance exercise in non-alcoholic fatty liver disease: A systematic review
|Journal of Hepatology|2016|504